Desmopressin
DDAVP · Stimate · Nocdurna (desmopressin acetate)
Indications for Desmopressin
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Central diabetes insipidus | Adults and pediatric patients (tablets ≥4 yr; nasal spray ≥4 yr; injection: all ages with careful monitoring) | Antidiuretic replacement | FDA Approved |
| Post-surgical / post-traumatic polyuria and polydipsia | Adults and pediatric patients following head trauma or pituitary surgery | Temporary antidiuretic | FDA Approved |
| Hemophilia A (mild-moderate, FVIII >5%) | Adults and pediatric patients without FVIII inhibitors | Hemostatic (FVIII release) | FDA Approved |
| Von Willebrand disease Type I (FVIII >5%) | Adults and pediatric patients with mild-moderate VWD | Hemostatic (VWF/FVIII release) | FDA Approved |
| Primary nocturnal enuresis | Pediatric patients ≥6 years (tablets only; nasal spray NOT indicated for PNE) | Antidiuretic (reduce nocturnal urine) | FDA Approved |
| Nocturia due to nocturnal polyuria | Adults (Nocdurna sublingual only) | Antidiuretic (reduce nocturnal urine) | FDA Approved |
Desmopressin is a synthetic analog of the natural pituitary hormone arginine vasopressin (ADH), with a structural modification (1-deamination and D-arginine substitution at position 8) that greatly enhances antidiuretic potency while virtually eliminating vasopressor activity. This design makes it safe for clinical use at antidiuretic doses without significant blood pressure effects. Desmopressin is the cornerstone of central diabetes insipidus management and a valuable hemostatic agent for mild bleeding disorders. It is ineffective in nephrogenic diabetes insipidus, where the kidneys cannot respond to ADH.
Uremic bleeding: IV desmopressin (0.3 mcg/kg) transiently improves hemostasis in patients with uremia by releasing VWF and shortening bleeding time. Evidence quality: Moderate (multiple small studies, guideline-supported).
Adjunct to prevent rapid sodium correction: Used with hypertonic saline in severe hyponatremia management to prevent osmotic demyelination syndrome. Evidence quality: Moderate (expert opinion, case series).
Platelet dysfunction (antiplatelet agents): Investigated for reversal of antiplatelet effects in intracranial hemorrhage. Evidence quality: Low (limited, mixed results).
Dosing
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Central DI — intranasal (adults) | 10 mcg (1 spray) at bedtime | 10–40 mcg/day divided BID | 40 mcg/day | Adjust morning and evening doses separately; titrate to control polyuria and polydipsia Each spray = 10 mcg; if dose <10 mcg, use rhinal tube |
| Central DI — oral tablets (adults) | 0.05 mg BID | 0.1–0.8 mg/day divided BID–TID | 1.2 mg/day | Oral dose is ~10–40× higher than intranasal due to low oral bioavailability (~0.16% vs IV) Tablet onset ~1 h; peak antidiuretic effect 4–7 h; duration up to 8–12 h |
| Central DI — injection (adults) | 2 mcg IV/SC daily or BID | 2–4 mcg/day IV/SC divided BID | 4 mcg/day | IV/SC dose is 1/10th of daily intranasal maintenance dose; do not dilute for DI use Convert from intranasal: start at 1/10th intranasal dose |
| Hemophilia A / VWD Type I — IV infusion | 0.3 mcg/kg IV over 15–30 min | Repeat after 8–12 h if needed | 0.3 mcg/kg (max 20 mcg per dose) | Give 30 min before procedure; measure FVIII and VWF before treatment; tachyphylaxis after 2–3 doses in 48 h Dilute in 50 mL NS for adults, 10 mL for children ≤10 kg |
| Hemophilia A / VWD Type I — intranasal (Stimate) | ≥50 kg: 300 mcg (1 spray/nostril); <50 kg: 150 mcg (1 spray in one nostril) | May repeat once based on response | 300 mcg per dose | Stimate spray = 150 mcg/spray (10× concentrated vs DDAVP spray); not interchangeable with the 10 mcg/spray formulation FVIII peaks ~60–90 min after intranasal dosing |
| Primary nocturnal enuresis — oral (children ≥6 yr) | 0.2 mg at bedtime | 0.2–0.6 mg at bedtime | 0.6 mg at bedtime | Restrict fluids from 1 h before to 8 h after dose; nasal spray NOT indicated for PNE (higher hyponatremia risk) Suspend during illness with fluid/electrolyte imbalance |
| Nocturia (adults) — sublingual (Nocdurna) | Women: 27.7 mcg SL; Men: 55.3 mcg SL at bedtime | Same (single fixed dose) | 27.7 mcg (women); 55.3 mcg (men) | Place under tongue 1 h before bedtime; limit fluids from 1 h before to 8 h after; check Na at baseline, within 7 days, at 1 month, then periodically Women require lower dose due to higher hyponatremia risk |
Desmopressin is available in multiple formulations with vastly different bioavailabilities and potencies. The DDAVP nasal spray (10 mcg/spray) is NOT the same as Stimate nasal spray (150 mcg/spray). Oral tablets require 10–40-fold higher doses than intranasal administration, and IV/SC doses are roughly 1/10th of intranasal doses. Switching between routes requires careful dose recalculation to avoid either inadequate antidiuresis or life-threatening hyponatremia.
When desmopressin is used for hemostasis in hemophilia A or VWD, the release of stored FVIII and VWF from endothelial Weibel-Palade bodies diminishes with repeated doses (tachyphylaxis). After 2–3 doses given within 48 hours, the hemostatic response is typically blunted. For surgeries requiring prolonged hemostatic coverage, factor concentrates should be available as backup. A test dose before elective surgery is recommended to confirm an adequate FVIII/VWF response.
Pharmacology
Mechanism of Action
Desmopressin is a selective agonist at the vasopressin V2 receptor, with minimal activity at the V1a receptor (which mediates vasoconstriction). This selectivity distinguishes it from native arginine vasopressin and allows clinical use at antidiuretic doses without significant hemodynamic effects. At the renal collecting duct, V2 receptor activation stimulates cAMP-dependent insertion of aquaporin-2 water channels into the luminal membrane, enabling free water reabsorption and producing concentrated urine. At the vascular endothelium, V2 receptor activation triggers release of von Willebrand factor (VWF) and factor VIII from endothelial Weibel-Palade bodies, providing a transient hemostatic effect that is exploited in the management of mild hemophilia A and Type I VWD. Desmopressin also releases tissue plasminogen activator (t-PA) from endothelial cells, though the clinical significance of this effect is modest at therapeutic doses.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | Bioavailability varies dramatically by route: IV/SC ~100%; intranasal ~3.3–4.1% (DDAVP spray); oral ~0.16% (vs IV) or ~5% (vs intranasal); SL ~0.25%; Tmax: oral 0.9–1.5 h; intranasal ~1.5 h | Dose equivalence across routes is NOT 1:1; oral doses are 10–40× higher than intranasal; switching formulations requires careful recalculation |
| Distribution | Vd 26.5 L (IV 2 mcg); MW 1183.34 Da; poor placental transfer; minimal breast milk excretion (<0.005% of dose) | Relatively large Vd for a peptide; safe in pregnancy (extensive clinical experience) and lactation |
| Metabolism | Minimally metabolized; resistant to enzymatic degradation due to 1-deamination and D-arginine substitution; not a CYP substrate | No significant drug-drug interactions via metabolic pathways; the structural modifications give desmopressin ~12× longer antidiuretic duration than native vasopressin |
| Elimination | Biphasic elimination profile (initial t½ 7.8 min, terminal 75.5 min per 2-compartment model, FDA nasal spray PI); mean terminal t½ ~2.8 h after IV by non-compartmental analysis (FDA tablets PI); t½ increases with renal impairment: 2.8 h (normal) → 4.0 h (mild RI) → 6.6 h (moderate RI) → 8.7 h (severe RI); ~52% excreted unchanged in urine within 24 h | Contraindicated in CrCl <50 mL/min due to markedly prolonged half-life and increased hyponatremia risk; the prolonged half-life relative to native vasopressin enables practical dosing intervals |
Side Effects
Adverse effect profiles differ by formulation and indication. Hyponatremia is the dominant safety concern across all routes and indications. The incidence data below are from the FDA prescribing information for each formulation and from controlled clinical trials.
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Headache | 4% (oral, PNE trials) vs 3% placebo | Most common drug-related adverse event in nocturnal enuresis trials; generally mild |
| Nasal congestion / Rhinitis | 3–8% (intranasal) | Route-specific to nasal formulations; chronic use may alter nasal mucosa |
| Nausea / Abdominal cramps | 2–5% (intranasal and injection) | More common with higher doses and rapid IV administration |
| Facial flushing | Common (injection) | V2-mediated vasodilation; usually transient; dose-dependent |
| Epistaxis | 3% (intranasal) | Related to intranasal administration technique; instruct proper use |
| Injection site reactions | Common (SC) | Burning, pain, erythema at injection site; generally mild |
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Hyponatremia (potentially life-threatening) | Uncommon with proper monitoring; higher risk in elderly, children, those with excessive fluid intake, and with nasal spray vs tablets for PNE | Hours to days; can occur at any time during chronic therapy | Ensure serum Na is normal before starting; restrict fluids; check Na within 1 week, at 1 month, then periodically; symptoms: headache, nausea, confusion, seizures, coma; if Na drops, reduce dose, increase fluid restriction, or discontinue; fatal cases reported |
| Hyponatremic seizures | Rare; primarily in children and elderly; higher with intranasal vs oral for PNE | Hours to days after dose, particularly with excessive fluid intake | Emergency management of seizures; correct hyponatremia carefully (risk of osmotic demyelination if corrected too rapidly); permanent discontinuation if seizures occur |
| Anaphylaxis / Severe hypersensitivity | Rare; fatal cases reported with IV administration | During or shortly after IV/intranasal administration | Monitor during IV administration; have resuscitation equipment available; permanently discontinue for serious allergic reactions |
| Thrombotic events (MI, CVA) | Rare; postmarketing reports with injection | During or shortly after hemostatic use | Use with caution in patients predisposed to thrombosis; contraindicated in VWD Type IIB (may cause thrombosis from platelet aggregation) |
| Severe hypotension / Hypertension | Rare; transient BP changes | During rapid IV infusion | Infuse IV over 15–30 minutes (not rapid push); monitor BP during administration, especially in patients with coronary artery disease |
Desmopressin-induced water retention combined with continued fluid intake can cause potentially fatal dilutional hyponatremia. The risk is highest in children, the elderly, patients with habitual/psychogenic polydipsia, and those taking concurrent medications that impair free water clearance (NSAIDs, SSRIs, TCAs, carbamazepine, chlorpromazine, opioids, lamotrigine). The nasal spray formulation carries a HIGHER hyponatremia risk than oral tablets for nocturnal enuresis (postmarketing data led to removal of the PNE indication from the nasal spray label). All patients must receive clear instructions on fluid restriction: limit intake from 1 hour before to 8 hours after an antidiuretic dose.
Drug Interactions
Desmopressin is not metabolized by CYP enzymes and has no significant pharmacokinetic interactions. All clinically relevant interactions are pharmacodynamic, primarily involving additive hyponatremia risk.
Monitoring
- Serum SodiumBefore initiation; within 7 days; at 1 month; then periodically
RoutineThe single most important monitoring parameter. Ensure Na is normal before starting or resuming therapy. More frequent monitoring in elderly, children, and those on medications that increase hyponatremia risk. If Na drops, consider dose reduction or discontinuation. Desmopressin is contraindicated in patients with hyponatremia or history of hyponatremia. - Fluid Intake & Urine OutputAt each visit; ongoing
RoutineMonitor urine volume and osmolality to assess antidiuretic response in DI. Restrict fluid from 1 h before to 8 h after antidiuretic dosing. Patients should be instructed to avoid excessive fluid intake. In DI management, aim for adequate sleep duration with normal water turnover. - Factor VIII / VWF LevelsBefore first hemostatic dose; 30–60 min after dose
RoutineFor hemophilia A/VWD use: confirm FVIII >5% before treatment; measure FVIII and VWF response after first dose (test dose) before elective surgery. Do not use if FVIII <5%. Monitor for tachyphylaxis with repeated doses. - Blood PressureDuring IV administration
Trigger-basedDesmopressin may cause transient hypotension (with compensatory tachycardia) or hypertension. Monitor BP especially in patients with coronary artery disease or hypertensive cardiovascular disease. - Renal FunctionBaseline; periodically (elderly)
RoutineContraindicated if CrCl <50 mL/min. Terminal half-life increases from 2.8 h (normal) to 8.7 h (severe renal impairment), markedly increasing hyponatremia risk. Renal function may decline with age, necessitating periodic monitoring in elderly patients. - Nasal MucosaPeriodically during chronic intranasal use
Trigger-basedChronic intranasal administration may cause nasal mucosa changes (edema, scarring, atrophy) leading to erratic absorption. If nasal mucosa abnormalities develop, switch to an alternative formulation (oral or injection).
Contraindications & Cautions
Absolute Contraindications
- Hyponatremia or history of hyponatremia: Desmopressin exacerbates water retention and dilutional hyponatremia.
- Moderate to severe renal impairment (CrCl <50 mL/min): Markedly prolonged half-life (2.8 h to 8.7 h) increases hyponatremia risk.
- Known hypersensitivity: To desmopressin acetate or any excipient. Fatal anaphylaxis has been reported with IV administration.
- Patients at increased risk of severe hyponatremia: Including those with excessive fluid intake, illnesses causing fluid/electrolyte imbalance, or concurrent use of loop diuretics or systemic/inhaled glucocorticoids.
- Von Willebrand disease Type IIB (for hemostatic use): Desmopressin may cause thrombocytopenia and thrombosis due to platelet aggregation.
Relative Contraindications (Specialist Input Recommended)
- Habitual or psychogenic polydipsia: Patients unable to restrict fluid intake are at very high risk of water intoxication.
- Heart failure or uncontrolled hypertension: Fluid retention may exacerbate cardiac decompensation.
- Conditions with increased intracranial pressure: Fluid retention could worsen cerebral edema.
- Nasal mucosa abnormalities (for intranasal use): Erratic absorption from scarring, edema, atrophy, or recent nasal surgery (e.g., transsphenoidal hypophysectomy).
Use with Caution
- Elderly patients: Greater risk of hyponatremia due to age-related renal impairment and decreased ability to concentrate urine.
- Pediatric patients: Require strict fluid restriction supervision; dose adjustments needed to prevent excessive decrease in plasma osmolality.
- Patients predisposed to thrombosis (for hemostatic use): Rare reports of MI and cerebrovascular thrombosis with injection.
- Concurrent medications increasing hyponatremia risk: SSRIs, TCAs, NSAIDs, carbamazepine, opioids, lamotrigine, chlorpromazine.
Desmopressin can cause hyponatremia, which may be life-threatening if severe. Ensure serum sodium concentration is normal before starting or resuming therapy. Monitor serum sodium within the first week and at one month after initiating or resuming therapy, then periodically. Patients must be instructed to restrict fluid intake. Signs and symptoms of hyponatremia include headache, nausea, vomiting, weight gain, restlessness, fatigue, lethargy, disorientation, muscle weakness, cramps, and confusion. Severe hyponatremia may cause seizures, coma, and respiratory arrest. The nasal spray formulation is NOT indicated for primary nocturnal enuresis due to a higher risk of hyponatremia and hyponatremic seizures compared with oral tablets in postmarketing reports.
Patient Counselling
Purpose of Therapy
Desmopressin replaces or supplements the effect of the natural antidiuretic hormone that your body may not be producing enough of (in diabetes insipidus), or it temporarily boosts certain blood-clotting factors (in bleeding disorders). The way you take it and your dose depend on the condition being treated. Follow your specific instructions carefully.
How to Take
Desmopressin comes in several forms: tablets, nasal spray, sublingual tablets, and injection. Your healthcare provider will prescribe the correct formulation and dose for your condition. Do not switch between formulations without medical guidance, as the doses are very different between routes.
Sources
- DDAVP (desmopressin acetate) injection prescribing information. Ferring Pharmaceuticals. Revised September 2022. FDA LabelPrimary injection PI with dosing for central DI and hemophilia A/VWD, PK data, adverse reactions, and updated hyponatremia warnings.
- Desmopressin Acetate Tablets prescribing information. Ferring Pharmaceuticals. Revised 2019. FDA LabelOral tablet PI with PK data (Vd 26.5 L, t½ 2.8 h, bioavailability ~0.16% vs IV, renal impairment half-life data), dosing for DI and PNE, and adverse reactions.
- DDAVP Nasal Spray (desmopressin acetate) prescribing information. Ferring Pharmaceuticals. Revised October 2018. FDA LabelIntranasal spray PI for DI; notes that nasal spray is NOT indicated for PNE due to higher hyponatremia risk; includes PK, dosing, and nasal mucosa precautions.
- Mannucci PM, Ruggeri ZM, Pareti FI, Capitanio A. 1-Deamino-8-D-arginine vasopressin: a new pharmacological approach to the management of haemophilia and von Willebrand’s diseases. Lancet. 1977;1(8017):869-872. DOI: 10.1016/S0140-6736(77)91197-7Landmark paper establishing desmopressin as a hemostatic agent by demonstrating its ability to raise factor VIII and VWF levels in hemophilia A and VWD patients.
- Sterns RH. Disorders of plasma sodium: causes, consequences, and correction. N Engl J Med. 2015;372(1):55-65. DOI: 10.1056/NEJMra1404489Comprehensive review of hyponatremia pathophysiology and management, including the role of desmopressin in both causing and treating sodium disorders.
- Glazener CM, Evans JH. Desmopressin for nocturnal enuresis in children. Cochrane Database Syst Rev. 2002;(3):CD002112. DOI: 10.1002/14651858.CD002112Cochrane systematic review of desmopressin for nocturnal enuresis: reduces wet nights by 1–2 per week compared to placebo; ~25% achieve short-term dryness; high relapse rate upon discontinuation.
- Christ-Crain M, Bichet DG, Fenske WK, et al. Diabetes insipidus. Nat Rev Dis Primers. 2019;5(1):54. DOI: 10.1038/s41572-019-0103-2Comprehensive primer on diabetes insipidus pathophysiology, diagnosis, and management with desmopressin as first-line therapy for central DI.
- Connell NT, Flood VH, Brber A, et al. ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease. Blood Adv. 2021;5(1):301-325. DOI: 10.1182/bloodadvances.2020003264Joint ASH/ISTH/NHF/WFH guideline recommending desmopressin as first-line therapy for minor bleeding or prophylaxis in responsive VWD Type 1 patients.
- Osterberg O, Savic RM, Karlsson MO, et al. Pharmacokinetics of desmopressin administrated as an oral lyophilisate dosage form in children with primary nocturnal enuresis and healthy adults. J Clin Pharmacol. 2006;46(10):1204-1211. DOI: 10.1177/0091270006291838Population PK study establishing oral lyophilisate bioavailability (~0.25%) and supporting the dose relationship between oral and sublingual formulations.
- Harris AS, Ohlin M, Lethagen S, Nilsson IM. Effects of concentration and volume on nasal bioavailability and biological response to desmopressin. J Pharm Sci. 1988;77(4):337-339. DOI: 10.1002/jps.2600770412Established that intranasal bioavailability is volume- and concentration-dependent (9–20% depending on delivery technique), informing the design of the Stimate high-concentration spray.
- Fjellestad-Paulsen A, Tubiana-Rufi N, Harris A, Czernichow P. Central diabetes insipidus in children: antidiuretic effect and pharmacokinetics of intranasal and peroral DDAVP. Acta Endocrinol (Copenh). 1987;115(3):307-312. DOI: 10.1530/acta.0.1150307Pediatric PK study establishing oral-to-intranasal dose conversion ratios and demonstrating ~10–40-fold dose difference between routes in children with DI.
- Kim RJ, Malattia C, Allen M, Moshang T Jr, Maghnie M. Vasopressin and desmopressin in central diabetes insipidus: adverse effects and clinical considerations. Pediatr Endocrinol Rev. 2004;2 Suppl 1:115-123. PMID: 16456490Review of desmopressin adverse effects in central DI, including hyponatremia mechanisms, risk factors, and prevention strategies.